Radiologists armed with millions of reports launching new study to pin down incidental findings
University of Washington Medicine radiologists are launching a new study to better understand incidental findings, including their associated costs, the Seattle-based university announced Monday.
With advances in medical imaging and an aging population, “incidentalomas” are increasingly common. Most of the time such findings are low-risk, but they can yield early cancers. It’s in the unknown middle grey area where follow-up scans, biopsies and costs begin to pile up.
“These apparent cancers have a wide spectrum of appearances. When we identify them, we usually don’t know whether they represent a cancer or whether there is short- or long-term risk,” Martin Gunn, MD, professor of radiology at UW Medicine, explained May 10. “We usually recommend follow-up with advanced imaging like ultrasound, CT, MRI, or nuclear medicine to find out and to ensure it does not grow.”
Gunn will co-lead a four-year study analyzing some 4 million radiology reports to assess how incidental findings impact morbidity, mortality and the cost-effectiveness of follow-up imaging and biopsies.
Backed by $2 million from the National Cancer Institutes, the group will focus on six common incidental lesions: lung, liver, kidney, pancreas, adrenal and thyroid gland.
Based off their findings and using software that automatically extracts information from radiology reports, the investigators will develop a database of records outlining follow-up costs, diagnoses and whether the finding led to a poor outcome. The tool will also list comorbidities and demographic info that may guide patients’ long-term health.
Take lung nodules for example, Gunn explained. Low-risk individuals with an incidentaloma of smaller than 6 millimeters face a cancer risk of less than 1%. That patient would only receive follow-up if they had a smoking history, he noted.
“At the other end of the spectrum, if the lung nodule is more than 1 centimeter, the cancer risk is substantially higher,” Gunn said. “So we’re hoping to better identify which cases are most appropriate to follow up, and what’s the best way to do that.”